Narcolepsy drug trial cut short – early results show promise for daytime alertness
NCT ID NCT06179407
First seen Apr 24, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This early-stage study tested an experimental drug called MK-6552 in 9 people with narcolepsy type 1, a condition that causes sudden sleep attacks. The goal was to see if the drug could help them stay awake longer during the day and to check for side effects. The trial was stopped early, but researchers were looking at how the drug moves through the body and whether it improves sleep latency (time to fall asleep).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bogan Sleep Consultants ( Site 0001)
Columbia, South Carolina, 29201, United States
-
Delta Waves, Inc. ( Site 0008)
Colorado Springs, Colorado, 80918, United States
-
FutureSearch Trials of Neurology ( Site 0004)
Austin, Texas, 78731, United States
-
NeuroTrials Research Inc ( Site 0006)
Atlanta, Georgia, 30328, United States
-
Teradan Clinical Trials, LLC ( Site 0005)
Brandon, Florida, 33511, United States
Conditions
Explore the condition pages connected to this study.